Physician profile
Olivia Burch
NPI 1982247888
$2,195.45
in general payments reported to CMS, 2019-2025
25 companies · $1,631 in 2025
The $1,631 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $273 · 2023: $124 · 2024: $24.06 · 2025: $1,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $249.87 | 2024-2025 | Korlym |
| Novo Nordisk INC | $233.67 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $223.83 | 2025 | |
| Lilly USA, LLC | $210.89 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $186.06 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $142.33 | 2025 | Recorlev |
| Astellas Pharma US INC | $138.18 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $128.67 | 2022-2025 | Farxiga |
| Tandem Diabetes Care, INC. | $122.14 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.96 | 2021-2023 | Jardiance |
| Esperion Therapeutics, INC. | $62.43 | 2025 | Nexletol |
| Stryker Corporation | $54.50 | 2025 | Clottriever Bold Catheter |
| Novartis Pharmaceuticals Corporation | $39.90 | 2022-2023 | |
| Glaxosmithkline, LLC. | $38.86 | 2021-2022 | |
| Sequel Med Tech, LLC | $37.73 | 2025 | Twiist |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.38 | 2025 | Evenity |
| Dexcom, INC. | $28.68 | 2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $28.23 | 2025 | Omnipod |
| Radius Health, INC. | $23.22 | 2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $21.26 | 2025 | |
| Amneal Pharmaceuticals LLC | $20.06 | 2025 | Unithroid |
| Avanir Pharmaceuticals, INC. | $17.06 | 2022 | |
| Averitas Pharma INC. | $17.01 | 2025 | Qutenza |
| Agile Therapeutics, INC. | $13.68 | 2021 | |
| Merck Sharp & Dohme LLC | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Burch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.